Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Sustained-release axitinib hydrogel shows promising efficacy and safety in wet age-related macular degeneration and diabetic retinopathy, setting foundation …
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Commercial partnership targets scalability, 24/7 PET imaging product access, and future expansion for next-gen cancer diagnostics.
Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Once-monthly subcutaneous treatment offers new option for preventing hereditary angioedema attacks across all patient types from therapy initiation.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
